Association between fibroblast growth factor 23 and bone metabolism in peritoneal dialysis patients
10.3760/cma.j.issn.1001-7097.2011.08.005
- VernacularTitle:腹膜透析患者成纤维细胞生长因子23与骨代谢的关系
- Author:
Weihua LIU
;
Qiaoling ZHOU
;
Xiang AO
;
Weisheng PENG
;
Jinghua YANG
;
Xiaozhao LI
- Publication Type:Journal Article
- Keywords:
Peritoneal dialysis;
Fibroblast growth factor 23;
Bone density;
Calciumphosphorus metabolism
- From:
Chinese Journal of Nephrology
2011;27(8):572-575
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the association between fibroblast growth factor 23 (FGF-23) and calcium (Ca)-phosphorus(P) metabolism and bone mineral density (BMD) in patients on peritoneal dialysis.Methods Fifty-nine patients undergoing continuous ambulatory peritoneal dialysis(CAPD) were enrolled in this study.These patients were divided into three groups as normal, osteopenic and osteoporotic, according to World Health Organization criteria based on bone mineral density T scores.Another 30 healthy people were also enrolled as control group.Levels of serum FGF-23 and 1,25 (OH)2VitD3 were measured by ELISA.Parathyroid horomone(PTH) was detected by immunoradiometric assay.Calcium and phosphorus were assessed with autobiochemistry machine.Bone density was studied by dual-energy X-ray absorptiometry (DEXA).Results The incidences of osteoporosis at the femur neck and lumbar spine in CAPD patients were 23.7％ and 35.6％, respectively.Among three groups of CADP patients, no significant differences were found in the levels of serum FGF-23, while the level of serum FGF-23 in CAPD group was higher than that in control gronp(P＜0.01).A positive correlation was found between log [FGF-23]and serum phosphorus(r=0.604, P＜0.01).However, a negative correlation was found between log[FGF-23]and 1,25(OH)2VitD3 and GFR (r=-0.401, P＜0.05; r=-0.651, P＜0.01).There were no correlations of log [FGF-23]with PTH, Ca, T scores and the duration of dialysis.Conclusions In CAPD patients, serum FGF-23 increases significantly.Serum phosphorus, renal function and 1,25(OH)2VitD3may play an important role in adjusting the level of serum FGF-23, while FGF-23 has no direct effect on bone mineralization in CAPD patients.
